Stanislav M. Borzyanitsa

Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia

Кристина Вячеславовна Орлова, Mikhail Yu. Fedyanin, Konstantin E. Simanenkov, Aleksandr S. Dergunov et autres

Background. Prior to the introduction of new agents — immune checkpoint inhibitors — for inoperable and/or metastatic melanoma (IMM), chemotherapy outcomes were generally poor. The median (Me) overall survival (OS) in IMM was no more than 6-9 months, and the Me of …

id, ru, us, gb, by (code pays fourni par la source)

125P Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice

Alexey Alexandrovich Tryakin, Mikhail Yu. Fedyanin, M. Mariam, Fedor Vladimirovich Moiseenko et autres

ru (code pays fourni par la source)

Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON

Alexey Alexandrovich Tryakin, Mikhail Yu. Fedyanin, Fedor Vladimirovich Moiseenko, Oleg V. Mironov et autres

Aim. To evaluate the safety and efficacy of long-term continuous use of Avegra BIOCAD (international nonproprietary name INN: bevacizumab) as a targeted therapy in patients with metastatic colorectal cancer in real-world practice. Materials and methods. The paper presents the interim results of …

id, ru (code pays fourni par la source)

Liver metastasis of colorectal cancer

Yu. A Magarill, Stanislav M. Borzyanitsa

тЕЗИСы КОНФЕРЕНцИИ 45 М.Н.Лобанов 1 , Я